טוען...
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Lenalidomide is an integral, yet evolving, part of current treatment pathways for both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). It is approved in combination with dexamethasone as first-line therapy for transplant-ineligible patients with N...
שמור ב:
| הוצא לאור ב: | Ann Hematol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Berlin Heidelberg
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7340649/ https://ncbi.nlm.nih.gov/pubmed/32296915 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04023-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|